




PHARMACEUTICAL 2020

Aeglea BioTherapeutics Inc.
Rank 213 of 358





RealRate

PHARMACEUTICAL 2020

Aeglea BioTherapeutics Inc.
Rank 213 of 358



The relative strengths and weaknesses of Aeglea BioTherapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Aeglea BioTherapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 54% points. The greatest weakness of Aeglea BioTherapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 73% points.

The company's Economic Capital Ratio, given in the ranking table, is 47%, being 11% points above the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	74,505
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	18,359
Liabilities, Non-Current	4,743
Other Assets	6,293
Other Compr. Net Income	78
Other Expenses	0
Other Liabilities	0
Other Net Income	2,080
Other Revenues	0
Property and Equipment	2,385
Research and Development	64,600
Selling, General and Administrative Expense	15,734

Output Variable	Value in 1000 USD
Assets	83,183
Liabilities	23,102
Expenses	80,334
Revenues	0
Stockholders Equity	60,081
Net Income	-78,254
Comprehensive Net Income	-78,215
Economic Capital Ratio	47%